Display Settings:

Format

Send to:

Choose Destination
    Int J Obstet Anesth. 2007 Jan;16(1):40-9. Epub 2006 Nov 27.

    Use of recombinant activated factor VII in massive obstetric haemorrhage.

    Source

    Obstetric Anaesthesia Department, Queen Charlotte's and Chelsea Hospital, and Department of Haematology, Hammersmith Hospital, London, UK.

    Abstract

    Massive obstetric haemorrhage is a life-threatening emergency that remains a major cause of maternal mortality. Conventional management is aimed at optimising uterine tone, replacing circulating volume and blood products, and surgery to achieve haemostasis. Recently there have been numerous reports of the (unlicensed) use of recombinant activated factor VII in the management of major obstetric haemorrhage. We report our experience of using it in the treatment of major post-partum haemorrhage in four previously healthy parturients. The published reports of recombinant activated factor VII use in post-partum haemorrhage (unrelated to pre-existing coagulopathies) are compared.

    PMID:
    17126006
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk